Statin cholesterol-lowering medications in Germany, Digi Mart USA News (Germany): At least 10.5 million people in Germany take cholesterol-lowering medications known as statins, according to the 2025 Arzneiverordnungsreport. The figure is rising, according to estimates from the DAK health insurer and the German Society of Lipidology.
One reason for the increase is that the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) now recommend lower target values for cholesterol in their guidelines than in the past. These guidelines are based on scientific studies, yet some users on social media claim that the lower targets reflect the profit interests of the pharmaceutical industry.
Others have spread fears about alleged side effects, and some patients say they refuse to take statins despite a doctor’s prescription. Claims about statins have also originated in the United States, where Health and Human Services Secretary Robert F.
Kennedy Jr. has repeatedly questioned the effectiveness and safety of the drugs.
Physicians and health organizations consulted for this report say the medical benefits of lower targets are well researched, and that cholesterol-lowering statins are effective and safe. Excess LDL cholesterol accumulates on artery walls, narrowing blood vessels and potentially leading to a heart attack or stroke.
Statins reduce LDL levels by blocking cholesterol production in the body.
Stefan Kabisch, a metabolic physician and study physician at the Charité Berlin, says the benefits of statins are clearly documented. “You can prevent heart attacks, you can prevent strokes, and you can prevent premature death in high-risk patients.”
Medication targets LDL cholesterol rather than the total cholesterol value cited in online comments. In 2011, European societies recommended that very high-risk patients have less than 70 milligrams of LDL cholesterol per 100 milliliters of blood.
Since 2019, the recommended value has been below 55 milligrams per deciliter, and for patients at extreme risk it is now below 40 milligrams per deciliter.
Targets are individualized. Doctors typically assess risk factors such as age, family history, blood pressure, smoking and pre-existing conditions.
Kabisch says that a patient with diabetes, a smoker, or a patient who has already had a heart attack would have a lower target. High-risk patients benefit most from statins, he says.
Raphael Schmieder, a cardiologist at the Herzzentrum München, explains that the lower targets reflect advances in research. Treatment is first given to the sickest patients, data are collected, and then lower thresholds are tested in further studies.
Several studies, including research from Harvard Medical School and the University of Chicago, indicate that lower LDL levels can further reduce the risk of heart attacks and strokes.
Some pharmaceutical companies co-financed certain studies, which both the pharmaceutical association Pharma Deutschland and Schmieder confirmed. Schmieder says this is common practice because large clinical trials are costly, and that funding alone does not make results less valid if financing is disclosed and studies follow scientific standards.
He adds that the evidence base for statins includes randomized trials, independent meta-analyses, and registry and real-world data.
More than 50 companies in Germany offer statin-containing cholesterol medications, according to Pharma Deutschland. Patent protection for statins has expired, and generic manufacturers produce them inexpensively, so profit margins are considerably lower.
The number of statin packages dispensed has risen by about 15.5 percent since 2022 to 34.1 million, and revenue in 2025 was about 192.4 million euros, an increase of roughly 4 percent since 2022.
According to health insurers DAK, AOK and the BKK umbrella organization, average annual drug spending per patient on statins is about 45 to 80 euros. Side effects are described by Kabisch and Schmieder as manageable, and severe side effects are extremely rare.
Some patients report muscle pain, in which case liver and muscle values are checked four to six weeks after starting treatment, and the dose or preparation can be adjusted. Schmieder says statins clearly offer more benefit than risk.
